Sign In
Buy ELVN
$59.42
-1.04 (-1.72%)
At Close: Aug 10, 2026
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
09:31pm, Tuesday, 21'st Apr 2020
Company also exceeds offering target Continue reading...
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
08:58pm, Tuesday, 21'st Apr 2020
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO, Stocks: KROS,XLRN,TSE:4503,BMY,FGEN,SRRA,IMRA,ZNTL, release date:Apr 21, 2020
Brokers Set Expectations for Passage Bio's Q1 2020 Earnings (NASDAQ:IMRA)
05:08am, Thursday, 09'th Apr 2020
Passage Bio (NASDAQ:IMRA) – Equities research analysts at SVB Leerink issued their Q1 2020 earnings per share estimates for Passage Bio in a report released on Monday, April 6th. SVB Leerink analyst
Zacks: Brokerages Set $30.00 Price Target for Passage Bio (NASDAQ:IMRA)
07:44am, Wednesday, 08'th Apr 2020
Passage Bio (NASDAQ:IMRA) has been given an average broker rating score of 1.25 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investme
Passage Bio (NASDAQ:IMRA) Coverage Initiated at Cowen
07:00am, Wednesday, 08'th Apr 2020
Research analysts at Cowen began coverage on shares of Passage Bio (NASDAQ:IMRA) in a report issued on Monday, Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a
Fly Intel: Top five analyst initiations JAZZ;CLAR;IMRA;IDYA;SLAB
02:42pm, Monday, 06'th Apr 2020
Fly Intel: Top five analyst initiations JAZZ CLAR IMRA IDYA SLAB
Passage Bio (NASDAQ:IMRA) Coverage Initiated by Analysts at Morgan Stanley
11:20am, Monday, 06'th Apr 2020
Equities researchers at Morgan Stanley assumed coverage on shares of Passage Bio (NASDAQ:IMRA) in a report issued on Monday, Briefing.com Automated Import reports. The firm set an “overweight” rat
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
06:03pm, Sunday, 05'th Apr 2020
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements i
Best ETFs for 2020: The Renaissance IPO ETF Got Major Help From Zoom
04:56pm, Friday, 27'th Mar 2020
The Renaissance IPO ETF could be one of the best ETFs this year as some of its holdings can soften the blow from the coronavirus pandemic.
Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown
11:02pm, Monday, 23'rd Mar 2020
The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans. “I think that fear
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
01:33pm, Friday, 13'th Mar 2020
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but
IMARA Announces Pricing of Initial Public Offering
01:57am, Thursday, 12'th Mar 2020
IMARA Inc. (the “Company”) (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic
